Status:
COMPLETED
Vitamin K2 Supplementation to Activate Matrix Gla Protein (MGP) as Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients
Lead Sponsor:
RWTH Aachen University
Conditions:
CKD 5D, Hemodialysis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Vascular calcification (VC) is a predictor of cardiovascular morbidity and mortality. Hemodialysis (HD) patients suffer from severe vascular calcifications. Matrix Gla protein (MGP) is a central calci...
Eligibility Criteria
Inclusion
- \> 18 years of age
- minimum of 3 months of hemodialysis
- written consent
Exclusion
- chronic or acute bowel disease
- soy bean allergy
- active Vitamin K Supplementation
- oral anticoagulation with vitamin K Antagonists (coumarins)
- systemic therapy using steroids
- positive history for thrombosis or embolism
- pregnancy
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT01407601
Start Date
January 1 2008
End Date
July 1 2009
Last Update
August 2 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
KfH Dialysis Unit Aachen
Aachen, North Rhine-Westphalia, Germany, 52074
2
University Hospital of the RWTH Aachen
Aachen, North Rhine-Westphalia, Germany, 52074
3
Dialysis Unit Erkelenz
Erkelenz, North Rhine-Westphalia, Germany, 41812